Pfizer announced that its experimental monthly obesity injection showed a side effect profile similar to existing weight-loss medications in a mid-stage clinical trial. The drug represents the company's entry into the rapidly growing obesity treatment market.

GLP-1 drugs, originally approved 20 years ago for diabetes treatment, have transformed obesity care by helping patients achieve significant weight reduction. More than 30 million people in the United States have used these medications, which include established treatments like Wegovy.

The class of drugs works by mimicking hormones that regulate blood sugar and appetite, leading to substantial weight loss in many patients. Medical experts suggest these medications may have broader applications beyond obesity and diabetes, potentially treating other obesity-related diseases including certain cancers.

However, GLP-1 medications have been associated with various side effects that have raised concerns among healthcare providers and patients. Reports of troubling reactions have emerged as usage has expanded, with patients experiencing widely varying responses to the treatments.

Pfizer's monthly dosing schedule could offer advantages over current options that require more frequent injections. The pharmaceutical company is competing in a market dominated by established players as demand for obesity treatments continues to grow rapidly.